Medtronic Initiates Global Study of Minimally Invasive Technology to Aid Lung Cancer Diagnosis

Medtronic's (NYSE: MDT) Minimally Invasive Therapies Group recently launched a 2,500-patient, international study to assess real-world impact of its superDimension(TM) navigation system. The Company developed the study to support and validate the superDimension system, which the Company hopes will become the global standard-of-care for obtaining lung tissue biopsies from the periphery of the lungs1. The LungGPS(TM) technology used in the superDimension system is the first of its kind to enable Electromagnetic Navigation Bronchoscopy procedures (also known as ENB procedures). ENB procedures provide a minimally invasive approach to access difficult-to-reach areas of the lung, which can aid in the diagnosis of lung disease and thereby lead to earlier, personalized treatment - potentially saving lives. With a historical lack of effective, non-invasive diagnostic technologies, lung cancer remains the number one cancer killer in the world, accounting for more cancer deaths than breast, colon and prostate cancer combined2. See full press release